U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. About FDA
  3. FDA Organization
  4. Oncology Center of Excellence
  5. AURA3: Mouth or throat sores
  1. Section N/A

AURA3: Mouth or throat sores

Project Patient Voice is intended to be used with a healthcare professional when discussing the potential symptoms related to a cancer and cancer treatment. Do not rely on Project Patient Voice alone to make decisions about medical care. Do not use Project Patient Voice to substitute for advice from your health care professional. Conclusions about patient experiences with symptoms may be limited because not all symptoms may have been captured by the patient-reported questionnaire.

← Back to summary table

Download symptom data (XLSX, 24KB)

In AURA3 Study, Patients Were Asked: "In the last 7 days, what was the SEVERITY of your MOUTH OR THROAT SORES at their WORST?"

Patients scored the severity of their Mouth or Throat Sores on a 5-point scale (None, Mild, Moderate, Severe, Very Severe)

Patient-Reported Mouth or Throat Sores During the First 24 Weeks on Treatment for Patients Who Completed a Questionnaire:

Figure 1 shows the percentage of patients reporting the severity of their Mouth or Throat Sores at each time point. For example, at week 2, 18% of patients taking Tagrisso reported Mouth or Throat Sores (ranging from Mild to Severe). The range of patients who had any Mouth or Throat Sores during the first 24 weeks of treatment with Tagrisso was between 14% - 31%. Click here for more information on how to read the graphs below.

Figure 1. Patient-Reported Mouth or Throat Sores During the First 24 Weeks on Treatment

Two stacked bar charts, one for Tagrisso and the other for chemotherapy, showing proportion of patients reporting the severity of mouth or throat sores at each time point through the first 24 weeks of treatment. For example, at week 2, 18% of patients taking Tagrisso reported mouth or throat sores (ranging from mild to severe).

All responses from patients' experiences just before and up to week 24 on-treatment were included in the analysis. Some patients did not report their symptoms every week, therefore the number of patients may vary between weeks. Furthermore, not all patients remained on the treatment for 24 weeks (e.g., some stop treatment for worsening disease) which is a reason for the change in the number of patients over the course of treatment.

Worst Response Option for Mouth or Throat Sores That Patients Reported During the First 24 Weeks on Treatment

Figure 2. Worst Patient-Reported Mouth or Throat Sores During the First 24 Weeks on Treatment

Two pie charts, one for Tagrisso and the other for chemotherapy, summarizing the percentage of patients by worst reported mouth or throat sores during the first 24 weeks of the clinical trial. In the Tagrisso arm, None (41%), Mild (33%), Moderate (14%), Severe (9%) and Very severe (3%). In the chemotherapy arm, None (33%), Mild (45%), Moderate (13%), Severe (7%) and Very severe (2%).

Patients with at least one on-treatment Mouth or Throat Sores score were included in the analysis. Tagrisso (N=99), Chemotherapy (N=55).

Some Patients Did Not Report Mouth or Throat Sores Before Treatment:

For patients that did not report Mouth or Throat Sores before treatment, Figure 3 shows the percentage of patients reporting the severity of their Mouth or Throat Sores between weeks 1 and 24.

Figure 3. Patient-Reported Mouth or Throat Sores During the First 24 Weeks on Treatment: Patients Without Mouth or Throat Sores Before Treatment

Two stacked bar charts, one for Tagrisso and the other for chemotherapy, which includes only those patients who had no mouth or throat sores before treatment. The bar charts show the proportion of patients reporting severity of mouth or throat sores at each time point through 24 weeks. For example, at week 2, 12% of patients taking Tagrisso reported mouth or throat sores (ranging from mild to severe).

All responses from patients who did not report Mouth or Throat Sores before treatment were included in the analysis. Some patients did not report their symptoms every week, therefore the number of patients may vary between weeks. Furthermore, not all patients remained on the treatment for 24 weeks (e.g., some stop treatment for worsening disease) which is a reason for the change in the number of patients over the course of treatment.

Worst Response Option for Mouth or Throat Sores That Patients Reported During the First 24 Weeks on Treatment, for Patients Who Did Not Have Mouth or Throat Sores Before Treatment:

Figure 4. Worst Patient-Reported Mouth or Throat Sores During the First 24 Weeks on Treatment: Patients Without Mouth or Throat Sores Before Treatment

Two pie charts, one for Tagrisso and the other for chemotherapy, which includes only those patients who had no mouth or throat sores before treatment. The pie charts summarize the percentage of patients by worst reported mouth or throat sores. In the Tagrisso arm, None (52%), Mild (32%), Moderate (8%), Severe (6%) and Very severe (2%). In the chemotherapy arm, None (30%), Mild (53%), Moderate (8%), Severe (6%) and Very severe (3%).

Patients who had no Mouth or Throat Sores before treatment and at least one on-treatment Mouth or Throat Sores score were included in the analysis. Tagrisso (N=63), Chemotherapy (N=36).

Back to Top